Login to Your Account



Syndax shares sizzle on signal in entinostat/Keytruda combo effort

By Marie Powers
News Editor

Wednesday, May 17, 2017

Despite "very interesting" preclinical data emerging on a heap of immuno-oncology molecules, "you still have to go into patients and show that it works," said Briggs Morrison, CEO of Syndax Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription